Home › Research › Biomarkers
Modulatory effect of glial fibrillary acidic protein (GFAP) levels on the association between plasma p ‐tau217 levels and cognitive decline in older adults
Elizabeth Valeriano-Lorenzo, Mario Emiliano Ricciardi, Sonia Wagner, Minerva Martinez, Belén Frades, María Ascensión Zea‐Sevilla, Meritxell Valenti, Teodoro del Ser et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Additionally, growing evidence suggests that neuroinflammation may modulate the effects of tau spread on cognitive impairment in AD [Peretti, Débora E., et al., Brain 147.12 (2024): 4094‐4104.]. Result 58(16,4%) participants were classified as p ‐tau217+, 176 (49,7%) as GFAP+, and 173(48,9%) showed GFAP fast.rate . Participants with p ‐tau217+ and higher annual GFAPfast.rate showed a significantly faster cognitive decline (βTime*pTau217*GFAP fast.rate = ‐0.158; p <0.001) than those with non‐GFAP fast.rate (Figure 1). However, baseline levels of GFAP and p ‐tau217 did not show a significant interaction (βTime*pTau217*GFAP baseline = ‐0.076; p = 0.094) (Figure 2). Conclusion Our results indicate that GFAP fast.rate modulates the relationship between p ‐tau217 and cognitive decline independently of age, sex and ApoE4, with a stronger decline observed in individuals with p ‐tau217+ who likely present a reactive astrogliosis.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 354 participants. In older adults, those with positive p-tau217 and a faster annual rise in GFAP showed significantly faster cognitive decline than those without a fast GFAP rise. Reported effect size: 61.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Valeriano-Lorenzo, E., Ricciardi, M. E., Wagner, S., Martinez, M., Frades, B., Zea‐Sevilla, M. A., et al. (2025). Modulatory effect of glial fibrillary acidic protein (GFAP) levels on the association between plasma p ‐tau217 levels and cognitive decline in older adults. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_106267
Vancouver
Valeriano-Lorenzo E, Ricciardi ME, Wagner S, Martinez M, Frades B, Zea‐Sevilla MA, et al. Modulatory effect of glial fibrillary acidic protein (GFAP) levels on the association between plasma p ‐tau217 levels and cognitive decline in older adults. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_106267.
BibTeX
@article{valerianolorenzo2025-ec93d4d3,
author = {Valeriano-Lorenzo, Elizabeth and Ricciardi, Mario Emiliano and Wagner, Sonia and Martinez, Minerva and Frades, Belén and Zea‐Sevilla, María Ascensión and Valenti, Meritxell and del Ser, Teodoro and others},
title = {{Modulatory effect of glial fibrillary acidic protein (GFAP) levels on the association between plasma p ‐tau217 levels and cognitive decline in older adults}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_106267},
url = {https://doi.org/10.1002/alz70856_106267}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Additionally, growing evidence suggests that neuroinflammation may modulate the effects of tau spread on cognitive impairment in AD [Peretti, Débora E., et al., Brain 147.12 (2024): 4094‐4104.].
- Result 58(16,4%) participants were classified as p ‐tau217+, 176 (49,7%) as GFAP+, and 173(48,9%) showed GFAP fast.rate .
- Participants with p ‐tau217+ and higher annual GFAPfast.rate showed a significantly faster cognitive decline (βTime*pTau217*GFAP fast.rate = ‐0.158; p <0.001) than those with non‐GFAP fast.rate (Figure 1).
- However, baseline levels of GFAP and p ‐tau217 did not show a significant interaction (βTime*pTau217*GFAP baseline = ‐0.076; p = 0.094) (Figure 2).
- Conclusion Our results indicate that GFAP fast.rate modulates the relationship between p ‐tau217 and cognitive decline independently of age, sex and ApoE4, with a stronger decline observed in individuals with p ‐tau217+ who likely present a reactive astrogliosis.
Why it matters
In older adults, those with positive p-tau217 and a faster annual rise in GFAP showed significantly faster cognitive decline than those without a fast GFAP rise. Baseline GFAP and p-tau217 did not show a significant interaction, and the authors conclude that the rate of GFAP change modifies the link between p-tau217 and cognitive decline.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designlongitudinal study
- Participants354
- Effect size61.9%
- Evidence strengthModerate
How this study scored 46/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 44 of the 96 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 354 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Pascual Sanchez‐Juan holds only 4 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Instituto de Salud Carlos III: institution h-index 649 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 44 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 44 of the 96 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.